Nitric oxide synthase inhibitor, aminoguanidine, reduces inflammation and demyelination produced by Theiler's virus infection

John W. Rose, Kenneth E. Hill, Yoshiaki Wada, Caroline I.B. Kurtz, Ikuo Tsunoda, Robert S. Fujinami, Anne H. Cross

Research output: Contribution to journalArticlepeer-review

46 Scopus citations

Abstract

This study evaluated effects of the inducible nitric oxide synthase (iNOS) inhibitor, aminoguanidine (AG), on the neuropathology and clinical disease produced by Theiler's murine encephalomyelitis virus (TMEV) DA strain infection. Treatment with AG was started on day 7, 14, 28 or 66 post- inoculation and continued for a minimum of 21 days. Inflammation, demyelination and axonal necrosis were scored in a blinded fashion spinal cord sections from each mouse. Reduction in inflammation, demyelination and axonal necrosis was observed in mice treated with AG. Apoptosis within the spinal cord parenchyma and perivascular cuffs was significantly decreased. AG treatment resulted in delayed onset of clinical disease.

Original languageEnglish
Pages (from-to)82-89
Number of pages8
JournalJournal of Neuroimmunology
Volume81
Issue number1-2
DOIs
StatePublished - Jan 1998

Keywords

  • Aminoguanidine
  • Apoptosis
  • Nitric oxide synthase
  • Theiler's murine encephalomyelitis virus

Fingerprint

Dive into the research topics of 'Nitric oxide synthase inhibitor, aminoguanidine, reduces inflammation and demyelination produced by Theiler's virus infection'. Together they form a unique fingerprint.

Cite this